Clinical Study

S1826- A Phase III, Randomized Study Of Nivolumab (Opdivo) Plus Avd Or Brentuximab Vedotin (Adcetris) Plus Avd In Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Posted Date: Apr 23, 2020

  • Investigator: Tahir Latif
  • Specialties: Cancer, Lymphoma, Oncology
  • Type of Study: Drug

The goal of this study is to compare the progression-free survival (PFS) in patients with newly diagnosed advanced stage classical Hodgkin lymphoma randomized to N-AVD (nivolumab, doxorubicin,vinblastine, dacarbazine) versus that obtained with BV-AVD (brentuximab vedotin,doxorubicin, vinblastine, dacarbazine).


To Be Eligible: Must Have Diagnosis Of Hodgkins Lymphoma, Adequate Organ Function, No Previous Therapy For Study Cancer, No Hx Of Organ Transplant, No Active Intercurrent Illness Or Infection



For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.